UCSD School of Medicine, La Jolla, California, United States.
Gilead Sciences, Inc., Foster City, California, United States.
Biochem Pharmacol. 2018 May;151:282-290. doi: 10.1016/j.bcp.2018.01.041. Epub 2018 Feb 6.
Despite improved therapy, rheumatoid arthritis (RA) remains an unmet medical need. Previous efforts to validate therapeutic targets in the mitogen-activated protein kinase (MAPK) family have had minimal success. Therefore, we evaluated the potential for targeting an upstream MAPK, namely apoptosis signal-regulating kinase 1 (ASK1), as an alternative approach. ASK1 protein and gene expression were observed in RA and osteoarthritis (OA) synovium as determined by immunohistochemistry (IHC) and qPCR, respectively, particularly in the synovial intimal lining. For RA, but not OA synovium, ASK1 correlated with IL-1β and TNF gene expression. ASK1 was also expressed by cultured fibroblast-like synoviocytes (FLS), with significantly higher levels in RA compared with OA cells. IL-1β and TNF stimulation significantly increased ASK1 expression in a time-and concentration-dependent manner in cultured FLS. ASK1 promoter activity was significantly increased by IL-1β and TNF and was dependent on an upstream RelA binding motif. A selective small molecule ASK1 inhibitor reduced RA FLS invasion, migration and proliferation in vitro and decreased arthritis severity in the rat collagen-induced arthritis (CIA) model. In summary, our findings demonstrate that ASK1 modulates signaling pathways relevant to RA in vitro and in vivo. It is induced by inflammatory cytokines through the activation of NF-κB, which could provide some site- and event specificity. Thus, inhibitors of the upstream MAPK ASK1 could be a novel approach to treating inflammatory arthritis.
尽管治疗方法有所改善,但类风湿关节炎(RA)仍然是一个未满足的医学需求。以前在验证丝裂原活化蛋白激酶(MAPK)家族治疗靶点方面的努力收效甚微。因此,我们评估了将上游 MAPK,即凋亡信号调节激酶 1(ASK1)作为替代方法的潜力。通过免疫组织化学(IHC)和 qPCR 分别确定,RA 和骨关节炎(OA)滑膜中观察到 ASK1 蛋白和基因表达,特别是在滑膜内膜衬里中。对于 RA 滑膜,但不是 OA 滑膜,ASK1 与 IL-1β 和 TNF 基因表达相关。ASK1 还在培养的成纤维样滑膜细胞(FLS)中表达,RA 细胞中的表达水平明显高于 OA 细胞。IL-1β 和 TNF 以时间和浓度依赖性方式显著增加培养的 FLS 中的 ASK1 表达。IL-1β 和 TNF 显著增加 ASK1 启动子活性,并且依赖于上游 RelA 结合基序。选择性小分子 ASK1 抑制剂可减少 RA FLS 的体外侵袭、迁移和增殖,并降低胶原诱导关节炎(CIA)大鼠模型中的关节炎严重程度。总之,我们的研究结果表明,ASK1 在体外和体内调节与 RA 相关的信号通路。它通过 NF-κB 的激活被炎性细胞因子诱导,这可能提供一些部位和事件特异性。因此,上游 MAPK ASK1 的抑制剂可能是治疗炎症性关节炎的一种新方法。